Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system

被引:3
|
作者
Lettino, M
Cantù, F
Mariani, M
机构
[1] IRCCS, Policlin S Matteo, CCU Cardiol, Dept Cardiol, I-27100 Pavia, Italy
[2] Univ Pisa, Inst Cardiol, Cardiothorac Dept, Pisa, Italy
关键词
aspirin; atherosclerosis; cyclo-oxygenase; endothelial cells; platelets; prostaglandin;
D O I
10.1016/S1590-8658(01)80154-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Prostaglandins play important roles in the pathophysiological mechanism of action of platelets and endothelial cells in the cardiovascular system. The two isoforms of cyclo-oxygenase, respectively cyclo-oxygenase-1 and cyclo-oxygenase-2, are differently expressed in these cells. Activated platelets show a relatively large amount of cyclo-oxygenase-1, whereas endothelial cells have the gene for cyclo-oxygenase-2, the expression of which follows cell activation. In the atherosclerosis lesion, prostaglandin synthesis is mainly mediated by the inducible cyclo-oxygenase-2 expressed in macrophages/foam cells, smooth muscle cells and endothelial cells. Aspirin, a selective platelet cyclo-oxygenase-1 inhibitor, still remains the most extensively studied antiplatelet agent, even though there is growing evidence that many other compounds could be valuable either in association, or alternatives in antithrombotic therapy.
引用
收藏
页码:S12 / S20
页数:9
相关论文
共 50 条
  • [41] Cyclo-oxygenase-2 inhibition increases blood pressure in rats
    Höcherl, K
    Endemann, D
    Kammerl, MC
    Grobecker, HF
    Kurtz, A
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (08) : 1117 - 1126
  • [42] Drug Insight: cyclo-oxygenase-2 inhibitors—a critical appraisal
    Burkhard Hinz
    Bertold Renner
    Kay Brune
    Nature Clinical Practice Rheumatology, 2007, 3 : 552 - 560
  • [43] Systematic review: cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis
    Mehta, S.
    Boddy, A.
    Johnson, I. T.
    Rhodes, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (09) : 1321 - 1331
  • [44] Clinical Pharmacology of LumiracoxibA Selective Cyclo-Oxygenase-2 Inhibitor
    Christiane M. Rordorf
    Les Choi
    Paul Marshall
    James B. Mangold
    Clinical Pharmacokinetics, 2005, 44 : 1247 - 1266
  • [45] Drug Insight: cyclo-oxygenase-2 inhibitors - a critical appraisal
    Hinz, Burkhard
    Renner, Bertold
    Brune, Kay
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (10): : 552 - 560
  • [46] Cyclo-oxygenase-2 expression in oral squamous cell carcinoma
    Seyedmajidi, Maryam
    Shafaee, Shahryar
    Siadati, Sepideh
    Khorasani, Monireh
    Bijani, Ali
    Ghasemi, Nafiseh
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (04) : 1024 - 1029
  • [47] Do selective cyclo-oxygenase-2 inhibitors have a future?
    Bannwarth, B
    DRUG SAFETY, 2005, 28 (03) : 183 - 189
  • [48] Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries
    Stemme, V
    Swedenborg, J
    Claesson, HE
    Hansson, GK
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2000, 20 (02) : 146 - 152
  • [49] Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?
    Bernard Bannwarth
    Drug Safety, 2005, 28 : 183 - 189
  • [50] The role of topical cyclo-oxygenase-2 inhibitors in skin cancer
    Zhan, Huichun
    Zheng, Haoyi
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2007, 8 (04) : 195 - 200